| [1] |
Siegel R, Ma J, Zou Z, et al. Cancer statistics, 2014 [J]. CA Cancer J Clin, 2014, 64(1): 9-29.
|
| [2] |
Chansky K, Sculier JP, Crowley JJ, et al. The International Association for the Study of Lung Cancer Staging Project: prognostic factors and pathologic TNM stage in surgically managed non-small cell lung cancer[J]. J Thorac Oncol, 2009, 4( 7): 792-801.
|
| [3] |
Jin Y, Tong DY, Tang LY, et al. Expressions of Osteopontin (OPN), alphanubeta3 and Pim-1 Associated with Poor Prognosis in Nonsmall Cell Lung Cancer (NSCLC) [J]. Chin J Cancer Res, 2012, 24 (2): 103-8.
|
| [4] |
Hoffman PC, Mauer AM , Vokes EE. Lung cancer [J]. Lancet, 20 00, 355(9202): 479-85.
|
| [5] |
Gao W, Wang BC, Di JS, et al. COX regression analysis of the prognosis of Non-small Cell Lung Cancer [J]. Zhong Liu Yan Jiu Yu Lin Chuang, 2003, 15(2): 91-3. [高卫, 王宝成, 狄剑时, 等. 非小细胞肺癌预后因素的Cox回归分析[J]. 肿瘤研究与临床, 20 03, 15(2): 91-3.]
|
| [6] |
Bogenrieder T, Herlyn M. Axis of evil: molecular mechanisms of cancer metastasis [J]. Oncogene, 2003, 22(42): 6524-36.
|
| [7] |
Wai PY, Kuo PC. Osteopontin: regulation in tumor metastasis[J]. Cancer Metastasis Rev, 2008, 27(1): 103-18.
|
| [8] |
Zhang J, Takahashi K, Takahashi F, et al. Differential osteopontin expression in lung cancer[J]. Cancer Lett, 2001, 171(2): 215-22.
|
| [9] |
Senger DR, Wirth DF, Hynes RO. Transformed mammalian cells secrete specific proteins and phosphoproteins[J]. Cell, 1979, 16 (4): 885-93.
|
| [10] |
Rangaswami H, Bulbule A, Kundu GC. Osteopontin: role in signaling and cancer progression[J].Trends Cell Biol, 2006, 16(2): 79 -87.
|
| [11] |
Rudland PS, Platt-Higgins A, El-Tanani M, et al. Prognostic significance of the metastasis-associated protein osteopontin in human breast cancer[J]. Cancer Res, 2002, 62(12): 3417-27.
|
| [12] |
Bramwell VH, Doig GS, Tuck AB, et al. Serial plasma osteopontin levels have prognostic value in metastatic breast cancer[J]. Clin Cancer Res, 2006, 12(11 Pt 1): 3337-43.
|
| [13] |
Hu Z, Lin D, Yuan J, et al. Overexpression of osteopontin is associated with more aggressive phenotypes in human non-small cell lung cancer[J]. Clin Cancer Res, 2005, 11(13): 4646-52.
|
| [14] |
Mack PC, Redman MW, Chansky K, et al. Lower osteopontin plasma levels are associated with superior outcomes in advanced non-small-cell lung cancer patients receiving platinum-based chemotherapy: SWOG Study S0003[J]. J Clin Oncol, 2008, 26 (29): 4771-6.
|
| [15] |
Shevde LA, Das S, Clark DW, et al. Osteopontin: an effector and an effect of tumor metastasis[J].Curr Mol Med, 2010, 10(1): 71 -81.
|
| [16] |
El-Tanani MK. Role of osteopontin in cellular signaling and metastatic phenotype[J]. Front. Biosci, 2008, 13: 4276-84.
|
| [17] |
Anborgh PH, Mutrie JC, Tuck AB, et al. Role of the metastasispromoting protein osteopontin in the tumour microenvironment [J] J Cell Mol Med, 2010, 14(8): 2037-44.
|
| [18] |
Johnston NI, Gunasekharan VK, Ravindranath A, et al. Osteopontin as a target for cancer therapy[J]. Front Biosci, 2008, 13 : 4361-72.
|
| [19] |
Weber GF. The cancer biomarker osteopontin: combination with other markers[J]. Cancer Genomics Proteomics, 2011, 8(6): 26 3-88.
|
下载:
